During the last session, NRX Pharmaceuticals Inc (NASDAQ:NRXP)’s traded shares were 12.6 million, with the beta value of the company hitting 1.20. At the end of the trading day, the stock’s price was $2.20, reflecting an intraday gain of 43.79% or $0.67. The 52-week high for the NRXP share is $7.33, that puts it down -233.18 from that peak though still a striking 50.0% gain since the share price plummeted to a 52-week low of $1.10. The company’s market capitalization is $38.26M, and the average intraday trading volume over the past 10 days was 2.08 million shares, and the average trade volume was 263.59K shares over the past three months.
NRX Pharmaceuticals Inc (NRXP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NRXP has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.29.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) trade information
NRX Pharmaceuticals Inc (NRXP) registered a 43.79% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 43.79% in intraday trading to $2.20, hitting a weekly high. The stock’s 5-day price performance is 54.93%, and it has moved by 67.94% in 30 days. Based on these gigs, the overall price performance for the year is -52.17%. The short interest in NRX Pharmaceuticals Inc (NASDAQ:NRXP) is 0.68 million shares and it means that shorts have 4.8 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies a decrease of -10.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, NRXP is trading at a premium of 9.09% off the target high and 9.09% off the low.
NRX Pharmaceuticals Inc (NRXP) estimates and forecasts
Statistics show that NRX Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. NRX Pharmaceuticals Inc (NRXP) shares have gone down -15.38% during the last six months, with a year-to-date growth rate more than the industry average at 52.70% against 16.70.
Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 5M by the end of current fiscal year.
While earnings are projected to return 53.58% in 2025.
NRXP Dividends
NRX Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
NRX Pharmaceuticals Inc (NASDAQ:NRXP)’s Major holders
NRX Pharmaceuticals Inc insiders own 23.56% of total outstanding shares while institutional holders control 6.05%, with the float percentage being 7.92%.
